KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalMarket CapitalizationNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Halozyme Therapeutics (HALO) Equity Average: 2011-2025

Historic Equity Average for Halozyme Therapeutics (HALO) over the last 14 years, with Sep 2025 value amounting to $418.3 million.

  • Halozyme Therapeutics' Equity Average rose 12.74% to $418.3 million in Q3 2025 from the same period last year, while for Sep 2025 it was $418.3 million, marking a year-over-year increase of 12.74%. This contributed to the annual value of $223.8 million for FY2024, which is 76.51% up from last year.
  • As of Q3 2025, Halozyme Therapeutics' Equity Average stood at $418.3 million, which was up 2.66% from $407.5 million recorded in Q2 2025.
  • Halozyme Therapeutics' 5-year Equity Average high stood at $423.0 million for Q1 2025, and its period low was $93.7 million during Q2 2021.
  • Moreover, its 3-year median value for Equity Average was $233.6 million (2024), whereas its average is $271.4 million.
  • As far as peak fluctuations go, Halozyme Therapeutics' Equity Average tumbled by 60.81% in 2023, and later surged by 223.41% in 2025.
  • Quarterly analysis of 5 years shows Halozyme Therapeutics' Equity Average stood at $239.3 million in 2021, then crashed by 44.26% to $133.4 million in 2022, then grew by 24.81% to $166.5 million in 2023, then spiked by 145.21% to $408.3 million in 2024, then rose by 12.74% to $418.3 million in 2025.
  • Its Equity Average was $418.3 million in Q3 2025, compared to $407.5 million in Q2 2025 and $423.0 million in Q1 2025.